欢迎来到天天文库
浏览记录
ID:55060671
大小:176.35 KB
页数:2页
时间:2020-05-08
《多烯磷脂酰胆碱与舒血宁注射液联合治疗非酒精性脂肪性肝炎疗效观察-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、现代医药卫生2014年5月30日第30卷第1O期JModMedHealth,May30,2014,Vo1.30,No.10·l465-·短篇论著-多烯磷脂酰胆碱与舒血宁注射液联合治疗非酒精性脂肪性肝炎疗效观察胡渊文(昆山市第一人民医院,江苏昆山215300)【摘要】目的观察多烯磷脂酰胆碱联合舒血宁注射液治疗非酒精性脂肪性肝炎(NASH)的疗效。方法将2012年1月至2013年7月收治的60例NASH患者随机分为治疗组和对照组,各30例;治疗组患者静脉滴注多烯磷脂酰胆碱和舒血宁注射液,对照组患者仅静脉滴注多烯磷脂酰胆碱;比较两组患者用药前后的肝功能变化及疗效。结果治疗组患
2、者肝功能指标治疗后较治疗前有显著改善,且优于对照组治疗后,差异均有统计学意义(P<0.05);治疗组总有效率(86,67%,26/30)高于对照组(3,33%,16/30),差异有统计学意义(7,94,P<0.O1)。结论多烯磷脂酰胆碱联合舒血宁注射液治疗NASH有显著疗效.值得临床借鉴。【关键词】磷脂酰胆碱类;肝炎;治疗结果;非酒精性脂肪性肝炎;舒血宁注射液doi:10.3969/j.issn.1009.5519.2014.10.01l文献标识码:A文章编号:1009—5519(2014)10.146502Clinicalobservationofpolyenepho
3、sphatidylcholineinjectionandShuxueninginjectioninthetreatmentofnon-alcoholicsteatohepatitisHuYuanwen(KunshanMunicipalFirstPeoplesHospital,Kunshan,JianSsu215300,China)【Abstract】objectiveToobservethecurativeefectofpolyenephosphatidylcholineinjectioncombinedwithShuxuen-inginjectioninthetrea
4、tmentofnon—alcoholicsteatohepatitis(NASH).MethodsAtotalof60patientswithNASH,whoweretreatedfromJanuary2012toJune2013,wererandomizedintotreatmentgroupandcontrolgroup,30easesineachgroup.ThetreatmentgroupadoptedintravenousdripofpolyenephosphatidylcholineandShuxuening,whilethecontrolgrouponly
5、usedpolyenephosphatidylcholineforintravenousdrip.Thechangesofliverfunctionandcurativeefectbeforeandaftermedicationbetweenthetwogroupswerecompared.ResultsTheliverfunctioninthetreatmentgroupaftermedicationimprovedmoreobvious—lythanthatbeforemedication,and山ediferencehadstatisticalsignifican
6、ce(P<0.05).Thetotaleffectiveratewas86.67%(26/30)inthetreatmentgroup,whichwashigherthanthatinthecontrolgroup(3.33%,16/30),andthediferencehadstatisticalsignificance(:7.94,P<0.O1).ConclusionThepolyenephosphatidylcholinecombinedwithShuxueninginjectionhasobviouseficacyforNASH,SOitisworthyofre
7、ferenceinclinic.【Keywords】Phosphatidylcholines;Hepatitis;Treatmentoutcome;Non—alcoholicsteatohepatitis;Shuxueninginjection近来研究表明,约20%t~酒精性脂肪性肝炎(NASH)可进展注射液250mL,静脉滴注,每天1次;治疗组患者在对照组基础为肝硬化.30%一40%患者死于肝相关疾病,部分发生亚急性肝功上给予舒血宁注射液(生产厂家:石家庄神威药业有限公司,规格:能衰竭和肝细胞癌『l】。NASH定义为一种在病理学变化上肝
此文档下载收益归作者所有